Market News How it works Learn FAQ
| RCT 0.0827 8.67% | NU 12.59 -16.95% | EWZ 34.15 -19.82% | BBD 2.93 -28.01% | TGL 0.2427 9.57% | AZTR 1.53 113.99% | ITUB 7.7 -20.37% | XP 15.705 -48.36% | NVD 3.99 -4.77% | SRTM 0.3 -30.28% | WFF 0.0898 12.25% | SPCX 146.9 -0.40% | PBR 22.5 -13.99% | SHFS 0.094 -29.00% | SOXL 90.5 8.31% | INTC 90.47 4.04% | VALE 12 -3.23% | NVDA 216 2.39% | CLRO 4.97 52.92% | NOK 8.64 6.14% | JBLU 2.37 -9.71% | TSLL 10.76 10.25% | CRWV 55.19 1.76% | GCDT 0.1545 -12.27% | SOXS 47.98 -8.54% | RIG 6.53 1.87% | NWGL 0.0869 5.98% | ABEV 2.83 -14.24% | RWM 14.5 -0.34% | BITO 10.65 -1.66% | AAL 12.2 0.74% | GPUS 0.1785 5.68% | TSLG 5.38 10.47% | T 20.85 -0.38% | SGRY 23.25 47.62% | IREN 25.43 2.11% | INTR 4.68 -34.91% | SBS 4.73 -26.09% | NFLX 63.9 -2.96% | GRAB 2.71 -2.87% | TSLA 391.62 5.21% | QID 14.22 -2.27% | WULF 11.98 5.83% | TQQQ 68.43 3.23% | CIFR 7.71 -2.90% | RBNE 0.17 -10.53% | SID 0.9118 -22.73% | SPDN 8.5 -0.47% | VZ 43.1 -3.49% | LUCD 0.5007 21.82%
LELexaria Bioscience Corp. logo

Lexaria Bioscience Corp. (LEXX)

NASDAQ Capital Market · Currency in USD
$2.92 ▼ -0.16 (-5.19%)
At close: Oct 26, 4:00 PM ET. Market closed.

Summary

Previous Close
$3.08
Open
$2.88
Day's Range
$2.88 – $3.04
52 Week Range
$2.43 – $21.60
Volume
13,831
Avg. Volume
54,264
Market Cap
$4.83M
Beta (5Y Monthly)
0.34
PE Ratio (TTM)
--
EPS (TTM)
-$4.68
Earnings Date
Oct 28, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$1.50

Profile: Lexaria Bioscience Corp.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
7
CEO
Richard C. Christopher

Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations.

Earnings

Next report: Wed, Oct 28, 2026
EPS estimate -$0.90 · Revenue est. $50.00K
DateEst.Actual
Jul 13, 2026-$0.90-$1.20Miss
Apr 13, 2026-$1.05-$0.90Beat
Jan 13, 2026-$1.95-$1.05Beat
Nov 26, 2025-$2.40-$2.10Beat
Jul 14, 2025-$2.25-$3.15Miss
Apr 14, 2025-$2.40-$2.25Beat

Analyst view

Consensus price target
$1.50 ▼ -48.6%
Range $1.50 – $1.50
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on LEXX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.